The Use of Glucocorticoid in the Management of Adverse Effects Related to Immunocheckpoint Inhibitors
Immunocheckpoint inhibitors (ICIs) activated the patients’ tumor immunity to kill the tumor cell, and brought new hope to patients with tumor. However, a series of immunocheckpoint inhibitors related adverse effects (irAEs) may also occur based on immune injury. Glucocorticoids are the basis for the...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2019-10-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2019.10.02 |